No Correlation Between Lymphocyte Pharmacodynamics and Autoimmune Adverse Events Following Alemtuzumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis

Bart Van Wijmeersch¹, David Brandes², Matthew Carraro³, Giancarlo Comi⁴, Yang Mao-Draayer⁵, Guillermo Izquierdo⁶, Ho Jin Kim⁷, Sven G Meuth⁸, Gabriel Pardo⁹, Basil Sharrack¹⁰, Carlo Tornatore¹¹, Tjalf Ziemssen¹², Alan Jacobs¹³, Luke Chung¹³, Nadia Daizadeh¹³, Heinz Wiendl⁸; on behalf of the CARE-MS I, CARE-MS II, and CAMMS03409 Investigators

¹Rehabilitation & MS-Centre Overpelt, BIOMED, Hasselt University, Hasselt, Belgium; ²Hope MS Center, Knoxville, TN, USA; ³Novant Health, Charlotte, NC, USA; ⁴University Vita-Salute San Raffaele, Milan, Italy; ⁵University of Michigan Medical School, Ann Arbor, MI, USA; ⁶Virgen Macarena University Hospital, Seville, Spain; ⁷Research Institute and Hospital of National Cancer Center, Goyang, Korea; ⁸University of Münster, Münster, Germany; ⁹OMRF Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; ¹⁰Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; ¹¹Georgetown University Medical Center, Washington, DC, USA; ¹²Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany; ¹³Sanofi, Cambridge, MA, USA

SHORT TITLE: Lymphocytes and Autoimmunity Post-alemtuzumab

BACKGROUND: In the phase 3 CARE-MS I/II trials (NCT00530348/NCT00548405), 2 alemtuzumab courses significantly improved clinical/MRI outcomes versus SC IFNB-1a over 2 years in RRMS patients. The most commonly occurring autoimmune adverse event (AE) with alemtuzumab includes thyroid disease, with immune thrombocytopenia (ITP) and nephropathies occurring less frequently. Alemtuzumab efficacy was maintained in a 4-year extension (NCT00930553) in absence of continuous treatment. The effects of alemtuzumab over time may be due to its selective depletion and distinct pattern of repopulation of CD52-expressing T and B lymphocytes.

OBJECTIVE: To compare lymphocyte pharmacodynamics over Years 0–2 in alemtuzumab-treated patients with or without an autoimmune AE through Years 0–6, using pooled data from the CARE-MS I/II studies.

METHODS: Autoimmune AE monitoring occurred at baseline and monthly (ITP; nephropathies) or quarterly (thyroid) in Years 0–6 and continued for 48 months after the last alemtuzumab infusion. Lymphocytes were phenotyped by flow cytometry quarterly and at Months 1 and 13 (ie, 1 month after receiving alemtuzumab Courses 1 and 2, respectively). Pharmacodynamic assessments: total counts for lymphocytes, CD3⁺/CD4⁺/CD8⁺ T cells, and CD19⁺ B cells; subset analyses for CD4⁺/CD8⁺ T cells (naïve/memory/regulatory [Treg]) and CD19⁺ B cells (immature/mature/memory); CD19⁺ (total/immature/memory) to Treg (CD4⁺/CD8⁺) cell ratios. Lymphocyte pharmacodynamics over 2
years in patients with and without autoimmune AE incidence over 6 years (core/extension studies combined) were compared.

**RESULTS:** No difference in total lymphocyte or subset depletion or repopulation patterns was observed over 2 years in patients with or without autoimmune AEs through 6 years. No correlation was observed between autoimmune AEs and any CD19+/T_reg cell ratio.

**CONCLUSION:** The current analyses do not suggest that differences in lymphocyte depletion or repopulation kinetics predict the occurrence of autoimmune AEs in alemtuzumab-treated patients, although repopulation of specific B- or T-cell clones potentially expressing autoimmune antibodies remains to be determined.

**STUDY SUPPORT:** Sanofi and Bayer HealthCare Pharmaceuticals.

**DISCLOSURES:** BVW: Research and travel grants, honoraria for MS-expert advice, and speaking fees (Actelion, Bayer-Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi, and Teva). **DB:** Speaker panels (Biogen, Genentech, Mallinckrodt, Novartis, Sanofi, and Teva) and research support (Mallinckrodt and Novartis). **MC:** Speaking and consulting fees, and advisory honoraria (Biogen, Genentech, Genzyme, and Mallinckrodt). **GC:** Consulting fees (Actelion, Bayer, Merck Serono, Novartis, Sanofi, and Teva) and lecture fees (Bayer, Biogen Dompé, Merck Serono, Novartis, Sanofi, Serono, Symposia International Foundation, and Teva). **YM-D:** Consulting fees and/or grant support (Acorda, Bayer, Biogen, Celgene, Chugai, EMD Serono, Genzyme, Novartis, Questor, and Teva Neuroscience) and grant support (NIH NIAID Autoimmune Center of Excellence: UM1-AI1110557; NIH NINDO R01-NS080821). **GI:** Speaking and advisory fees (Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi, and Teva). **HJK:** Consulting and/or speaking fees (Bayer, Biogen, Celltrion, Eisai, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB); research support (Genzyme, Merck Serono, Ministry of Science & ICT, Teva-Handok, and UCB); steering committee member (MedImmune); co-editor (Multiple Sclerosis Journal – Experimental, Translational, and Clinical); and associate editor (Journal of Clinical Neurology). **SGM:** Honoraria for lecturing, travel expenses for attending meetings, and financial research support (Almirall, Amicus Therapeutics Germany, Bayer, Biogen, Celgene, Chugai Pharma, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, QuintilesIMS, Roche, Sanofi-Aventis, and Teva). **GP:** Speaking and advisory fees (Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi, and Teva). **BS:** Research and travel grants, honoraria for expert advice on MS, and speaking fees (Biogen, Merck, Novartis, Roche, Sanofi, and Teva). **CT:** Honoraria for attending advisory boards and research funding (Bayer, Biogen, Novartis, and Sanofi). **TZ:** Consulting or speaking fees (Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva) and grant/research support (Biogen, Novartis, Sanofi, and Teva). **AJ, LC, and ND:** Employees of Sanofi. **HW:** Consulting and/or speaking fees, and grant/research support (Bayer, Bayer Schering Pharma, Biogen, Elan Corporation, Lilly, Lundbeck, Merck Serono, Novartis, Novo Nordisk, Sanofi, and Teva Neuroscience).

This abstract will be presented by Wiendl H et al at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10–12, 2018, Berlin, Germany.